Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder

dc.creatorCarneiro Neto, Jose Abraão
dc.creatorSantos, Silvane Braga
dc.creatorOrge, Gloria Orge
dc.creatorTanajura, Davi
dc.creatorPassos, Lucia
dc.creatorOliveira, Cassius José
dc.creatorAndrade, Rosana
dc.creatorMelo, Cláudio Galeno de
dc.creatorBarroso, Ubirajara
dc.creatorCarvalho Filho, Edgar Marcelino
dc.date2018-06-26T17:55:09Z
dc.date2018-06-26T17:55:09Z
dc.date2018
dc.date.accessioned2023-09-26T22:13:08Z
dc.date.available2023-09-26T22:13:08Z
dc.identifierCARNEIRO NETO, J. A. et al. Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder. Brazilian Journal of Infectious Diseases, v. 22, n. 2, p. 79–84, 2018.
dc.identifier1413-8670
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/27131
dc.identifier10.1016/j.bjid.2017.10.009
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8876406
dc.descriptionTo evaluate the efficacy of the onabotulinum toxin type A in the treatment of HTLV-1 associated overactive bladder and its impact on quality of life (QoL). Methods: Case series with 10 patients with overactive bladder refractory to conservativetreatment with anticholinergic or physical therapy. They received 200Ui of onabotulinum-toxin type A intravesically and were evaluated by overactive bladder symptoms score(OABSS) and King’s Health Questionnaire.Results: The mean (SD) of the age was 52 + 14.5 years and 60% were female. All of them hadconfirmed detrusor overactivity on urodynamic study. Seven patients had HAM/TSP. Themedian and range of the OABSS was 13 (12–15) before therapy and decreased to 1.0 (0–12)on day 30 and to 03 (0–14) on day 90 (p < 0.0001). There was a significant improvement in 8 ofthe 9 domains of the King’s Health Questionnaire after the intervention. Hematuria, urinaryretention and urinary infection were the complications observed in 3 out of 10 patients. Themean time to request retreatment was 465 days.Conclusion: Onabotulinum toxin type A intravesically reduced the OABSS with last long effectand improved the quality of life of HTLV-1 infected patients with severe overactive bladder.
dc.formatapplication/pdf
dc.languageeng
dc.publisherElsevier
dc.rightsopen access
dc.subjectBexiga hiperativa
dc.subjectToxina onabotulínica
dc.subjectHTLV-1
dc.subjectOveractive bladder
dc.subjectOnabotulinum toxin
dc.subjectHTLV-1
dc.titleOnabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder
dc.typeArticle


Este ítem pertenece a la siguiente institución